Statement: Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.
Primary_evidence: Outcome Measurement:    Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee   cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST). CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs). PR for TLs is defined as a >=30% decrease in the sum of the longest diameter (LD) of TLs, taking as a reference the Baseline sum LD. For non-TLs, it is defined as the persistence of >=1 non-TL and no new TLs or non-TLs.   Time frame: From Baseline (Day 1) up to 6 months, evaluated every 12 weeks Results 1:    Arm/Group Title: Letrozole + Placebo   Arm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery.   Overall Number of Participants Analyzed: 48   Measure Type: Number   Unit of Measure: percentage of participants  CR: 2 PR: 58 Results 2:    Arm/Group Title: Letrozole + Lapatinib   Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery.   Overall Number of Participants Analyzed: 41   Measure Type: Number   Unit of Measure: percentage of participants  CR: 12 PR: 54